None (GDTC) is a publicly traded company. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies.
Analysis Summary
Balance sheet quality for GDTC: current ratio of 5.2, net cash position of $1.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.89 |
| Market Cap | $10M |
Financial Health
| Piotroski F-Score | 2 |
| Altman Z-Score | 5.96 |
Price Performance
| 1 month | -5.70% |
| 3 months | -17.96% |
| Year-to-date | -33.88% |
| 1 year | -52.87% |
| 3 years | -76.05% |
52-Week Range
| 52-week High | $3.68 |
| 52-week Low | $0.68 |
| Avg Volume (90d) | 63K |
Related companies: CLGN · ENLV · LSTA · MTVA · NCNA · NRSN · NRXS
More sections of GDTC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks